In BRAF mutated melanoma cell lines, the MEK/ERK pathway promotes the constitutive activation of mTOR through the p90 ribosomal S6 kinase RSK, inhibition of which abrogates tumor growth in mouse models (Romeo et al., 2013). Here, MTOR is linked to melanoma.